Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Lifeward (Nasdaq: LFWD) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, a condition satisfied on March 9, 2026. The Nasdaq Listing Qualifications Staff considers the prior bid price deficiency closed and Lifeward ordinary shares will continue trading on The Nasdaq Capital Market.
Positive
- Regained Nasdaq compliance by meeting $1.00 bid requirement on 3/9/2026
- Prior bid price deficiency classified as closed by Nasdaq staff
- Ordinary shares to remain listed and traded on The Nasdaq Capital Market
Negative
- Company experienced a prior minimum bid price deficiency before March 9, 2026
News Market Reaction – LFWD
In the Mar 11 session, LFWD gained 5.20%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Clinical partnership | Positive | -8.4% | Collaboration with Shirley Ryan AbilityLab to expand access to ReWalk exoskeleton. |
| Feb 25 | Technology acquisition | Positive | +20.2% | Agreement to acquire AI-enabled upper-body exoskeleton assets from Skelable. |
| Feb 20 | Reverse share split | Negative | -18.3% | Announcement of 1-for-12 reverse share split to support Nasdaq bid requirement. |
| Feb 17 | Coverage expansion | Positive | +3.3% | ReWalk exoskeleton coverage expanded across three major Medicare Advantage insurers. |
| Jan 13 | Strategic partnership | Positive | +9.2% | Oramed investment and partnership providing funding and oral delivery platform assets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LFWD’s news reactions mostly align with headline tone; strategic and reimbursement wins often saw positive moves, but one recent collaboration drew a negative response despite positive content.
Over the last few months, Lifeward reported several transformative steps, including a strategic Oramed partnership providing access to up to $47 million, expanded Medicare Advantage coverage for ReWalk reaching about 16 million beneficiaries, and a 1-for-12 reverse split to address Nasdaq’s $1.00 bid rule. It also pursued acquisitions such as Skelable’s upper-body exoskeleton technology and clinical collaborations. Today’s confirmation of regained bid-price compliance follows these capital structure and listing actions, effectively closing out the prior deficiency noted in earlier filings.
Key Terms
minimum bid price requirement regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule").
To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading "Risk Factors" in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2024 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact:
Almog Adar
Chief Financial Officer
Lifeward
E: media@golifeward.com
E: ir@golifeward.com
